PURPOSE Although the incidence of microsatellite instability (MSI) accounts for 10-15% of cases of colorectal cancer, its clinical application for all colorectal cancers has widened. We attempted to identify clinical and pathological parameters that may be helpful in selection of patients with MSI-high (MSI-H). MATERIALS AND METHODS A total of 120 resected colorectal cancers were enrolled retrospectively for this MSI study.
Polymerase chain reaction (PCR) and denaturing high performance liquid chromatography and/or real time PCR methods with five markers and immunohistochemistry (IHC) for MLH1 and MSH2 were performed for analysis of cancer and blood specimens. Clinico-pathologic parameters, including IHC, were investigated in order to determine their usefulness as predictive factors of MSI. RESULTS Among 120 cases of colorectal cancer, MSI was observed in 15 cases (12.5%), including 11 cases of MSI-H and four cases of MSI-low. Patients with MSI were younger, less than 50 years old, had a family history of cancer, Rt.
sided colon cancer and/or synchronous multiple colorectal cancer, mucinous histologic type, and serum carcinoembryonic antigen group in the normal range. Results of multivariate analysis showed Bethesda guidelines, Rt. sided and/or synchronous multiple colorectal cancer, and negative expression of IHC for MLH1, which was consistently associated with MSI-H. MSI-H colorectal tumors have met at least one of these three parameters and their sensitivity and specificity were 100% and 72.5%, respectively. CONCLUSION Bethesda guidelines, tumor location, and negative expression of MLH1 protein are important parameters for selection of patients with colorectal cancers for MSI testing. MSI testing is recommended for patients showing any of these three parameters.
Comparison of histopathologic and clinical characteristics of microsatellite instability in colorectal adenocarcinomas and its impact on survival Bilal Tunçtürk, Ulaş Alabalik, Ayşe Nur Keleş Biotechnology & Biotechnological Equipment.2024;[Epub] CrossRef
Interventional gastroenterology in oncology Vaibhav Wadhwa, Nicole Patel, Dheera Grover, Faisal S. Ali, Nirav Thosani CA: A Cancer Journal for Clinicians.2023; 73(3): 286. CrossRef
Molecular profiling of the colon cancer in South-Eastern Romania Razvan Catalin Popescu, Cristina Tocia, Costel Brînzan, Georgeta Camelia Cozaru, Mariana Deacu, Andrei Dumitru, Nicoleta Leopa, Anca Florentina Mitroi, Anca Nicolau, Eugen Dumitru Medicine.2021; 100(1): e24062. CrossRef
Potential Mechanism of Immune Evasion Associated with the Master Regulator ASCL2 in Microsatellite Stability in Colorectal Cancer Qian Yang, Guowei Huang, Liyan Li, Enmin Li, Liyan Xu, Carlo Cavaliere Journal of Immunology Research.2021; 2021: 1. CrossRef
Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer Zuzana Snahnicanova, Ivana Kasubova, Michal Kalman, Marian Grendar, Peter Mikolajcik, Eva Gabonova, Ludovit Laca, Martin Caprnda, Luis Rodrigo, Rachele Ciccocioppo, Peter Kruzliak, Lukas Plank, Zora Lasabova Clinical and Experimental Medicine.2020; 20(1): 87. CrossRef
Expression and significance of miR-654-5p and miR-376b-3p in patients with colon cancer Ping Li, Jia-Xun Cai, Fei Han, Jie Wang, Jia-Jie Zhou, Kai-Wen Shen, Liu-Hua Wang World Journal of Gastrointestinal Oncology.2020; 12(4): 492. CrossRef
Concomitant occurrence of primary renal non-Hodgkin lymphoma and a colon cancer Ji Li, Yabin Zou, Bin Wang, Xiangwei Meng, Xun Sun Medicine.2019; 98(10): e14802. CrossRef
Meta-analysis of the molecular associations of mucinous colorectal cancer I S Reynolds, S J Furney, E W Kay, D A McNamara, J H M Prehn, J P Burke British Journal of Surgery.2019; 106(6): 682. CrossRef
Association between clinicopathological characteristics and RAS mutation in colorectal cancer Johan Rimbert, Gaëlle Tachon, Audelaure Junca, Claire Villalva, Lucie Karayan-Tapon, David Tougeron Modern Pathology.2018; 31(3): 517. CrossRef
Deficient mismatch repair and RAS mutation in colorectal carcinoma patients: a retrospective study in Eastern China Xiangyan Zhang, Wenwen Ran, Jie Wu, Hong Li, Huamin Liu, Lili Wang, Yujing Xiao, Xiaonan Wang, Yujun Li, Xiaoming Xing PeerJ.2018; 6: e4341. CrossRef
Comparison of the eighth version of the American Joint Committee on Cancer manual to the seventh version for colorectal cancer: A retrospective review of our data Guo-Jun Tong, Gui-Yang Zhang, Jian Liu, Zhao-Zheng Zheng, Yan Chen, Ping-Ping Niu, Xu-Ting Xu World Journal of Clinical Oncology.2018; 9(7): 148. CrossRef
Analysis of factors influencing molecular testing at diagnostic of colorectal cancer Quentin Thiebault, Gautier Defossez, Lucie Karayan-Tapon, Pierre Ingrand, Christine Silvain, David Tougeron BMC Cancer.2017;[Epub] CrossRef
Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies Moritz Jesinghaus, Nicole Pfarr, Matthias Kloor, Volker Endris, Luca Tavernar, Alexander Muckenhuber, Magnus von Knebel Doeberitz, Roland Penzel, Wilko Weichert, Albrecht Stenzinger Genes, Chromosomes and Cancer.2016; 55(3): 268. CrossRef
The Immune Biology of Microsatellite-Unstable Cancer Matthias Kloor, Magnus von Knebel Doeberitz Trends in Cancer.2016; 2(3): 121. CrossRef
Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse Won Kyung Kang, Jin Kwon Lee, Seong Taek Oh, Sung Hak Lee, Chan Kwon Jung BMC Gastroenterology.2015;[Epub] CrossRef
KRASandBRAFgene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients Ju-Xiang Ye World Journal of Gastroenterology.2015; 21(5): 1595. CrossRef
Colorectal cancer Hermann Brenner, Matthias Kloor, Christian Peter Pox The Lancet.2014; 383(9927): 1490. CrossRef
AJCC Cancer Staging Manual 7th Edition Criteria for Colon Cancer: Do the Complex Modifications Improve Prognostic Assessment? Danielle M. Hari, Anna M. Leung, Ji-Hey Lee, Myung-Shin Sim, Brooke Vuong, Connie G. Chiu, Anton J. Bilchik Journal of the American College of Surgeons.2013; 217(2): 181. CrossRef